NCT05753501

First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Study Summary

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed. ABBV-101 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-101 and a dose expansion phase to determine the change in disease activity in participants with first line treatment (1L), second line or later of treatment (2L)+ CLL/SLL or third line or later of treatment (3L) non-GCB DLBCL. Approximately 340 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide. In the Dose Escalation phase of the study participants will receive escalating oral doses of ABBV-101, until the MAD/MTD is determined, as part of the approximately 88 month study duration. In the dose expansion phase of the study participants receive oral ABBV-101, as part of the approximately 88 month study duration . There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

Want to learn more about this trial?

Request More Info

Interventions

ABBV-101DRUG
Oral:Tablet

Study Locations

FacilityCityStateCountry
Arizona Oncology Associates, PC-HOPE /ID# 252351TempeArizonaUnited States
UC Irvine Medical Center /ID# 263020OrangeCaliforniaUnited States
Stanford University /ID# 249683Palo AltoCaliforniaUnited States
Rocky Mountain Cancer Centers - Lone Tree /ID# 252237Lone TreeColoradoUnited States
Northwestern University Feinberg School of Medicine /ID# 249347ChicagoIllinoisUnited States
Beth Israel Deaconess Medical Center /ID# 249302BostonMassachusettsUnited States
Rutgers Cancer Institute of New Jersey /ID# 249323New BrunswickNew JerseyUnited States
New York Oncology Hematology - Albany Cancer Center /ID# 252240AlbanyNew YorkUnited States
Northwell Health - Monter Cancer Center /ID# 250422Lake SuccessNew YorkUnited States
University of Rochester Medical Center /ID# 249324RochesterNew YorkUnited States
UC Health - Cincinnati /ID# 249299CincinnatiOhioUnited States
Oncology Assoc. of Oregon PC - WVCI and Research Ctr - Springfield /ID# 249309EugeneOregonUnited States
University of Pennsylvania /ID# 250341PhiladelphiaPennsylvaniaUnited States
MD Anderson Cancer Center /ID# 249293HoustonTexasUnited States
University Health Network_Princess Margaret Cancer Centre /ID# 253483TorontoOntarioCanada
CHUM Notre-Dame Hospital /ID# 253428MontrealQuebecCanada
Institut Bergonie /ID# 253664BordeauxGirondeFrance
CHU Montpellier - Hopital Saint Eloi /ID# 253666MontpellierHeraultFrance
CHRU Lille - Hopital Claude Huriez /ID# 253665LilleNordFrance
Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 256248NantesPays de la Loire RegionFrance
Institut Gustave Roussy /ID# 253662VillejuifVal-de-MarneFrance
Hopital Saint-Louis /ID# 253663ParisFrance
Universitaetsklinikum Ulm /ID# 253742UlmBaden-WurttembergGermany
Universitaetsklinikum Wuerzburg /ID# 254636WürzburgBavariaGermany
Universitaetsmedizin Rostock /ID# 259657RostockMecklenburg-VorpommernGermany
Universitaetsklinikum des Saarlandes /ID# 257435HomburgSaarlandGermany
Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 257431BerlinGermany
Universitaetsklinikum Hamburg-Eppendorf /ID# 264566HamburgGermany
Yitzhak Shamir Medical Center /ID# 254566ẔerifinCentral DistrictIsrael
Hadassah Medical Center-Hebrew University /ID# 251123JerusalemJerusalemIsrael
The Chaim Sheba Medical Center /ID# 251122Ramat GanTel AvivIsrael
Tel Aviv Sourasky Medical Center /ID# 259608Tel AvivTel AvivIsrael
IRCCS Ospedale San Raffaele /ID# 253531MilanMilanoItaly
ASST Grande Ospedale Metropolitano Niguarda /ID# 253532MilanMilanoItaly
A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 253530TurinPiedmontItaly
ASST Papa Giovanni XXIII /ID# 260317BergamoItaly
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 255172BolognaItaly
National Cancer Center Hospital East /ID# 250684Kashiwa-shiChibaJapan
Kyoto University Hospital /ID# 261837KyotoKyotoJapan
National Cancer Center Hospital /ID# 250680Chuo-kuTokyoJapan
The Cancer Institute Hospital Of JFCR /ID# 260375Koto-kuTokyoJapan
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 260196MajadahondaMadridSpain
Hospital Universitario Vall de Hebron /ID# 260447BarcelonaSpain
Hospital Universitario Ramon y Cajal /ID# 260450MadridSpain
Hospital Universitario Fundacion Jimenez Diaz /ID# 253654MadridSpain
Hospital Universitario HM Sanchinarro /ID# 253655MadridSpain
Hospital Universitario de Salamanca /ID# 253656SalamancaSpain
Addenbrookes Hospital /ID# 256242CambridgeCambridgeshireUnited Kingdom
Leicester Royal Infirmary /ID# 255171LeicesterEnglandUnited Kingdom
University College London Hospital /ID# 260202LondonGreater LondonUnited Kingdom
Kings College Hospital NHS Foundation Trust /ID# 253670LondonGreater LondonUnited Kingdom

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026